Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split
December 27, 2024 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”), today announced that a 1-for-12 reverse stock split of its outstanding shares of common...
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
December 18, 2024 07:00 ET
|
Tvardi Therapeutics
Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently...
Cara Therapeutics Announces Exploration of Strategic Alternatives
July 11, 2024 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., July 11, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that it has engaged Piper Sandler & Co. to act as its financial advisor for the process...
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
June 12, 2024 16:01 ET
|
Cara Therapeutics, Inc.
– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn.,...
Cara Therapeutics Reports First Quarter 2024 Financial Results
May 13, 2024 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
May 06, 2024 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., May 06, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
March 07, 2024 07:00 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., March 07, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
March 04, 2024 16:01 ET
|
Cara Therapeutics, Inc.
–Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal...
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
February 12, 2024 16:01 ET
|
Cara Therapeutics, Inc.
STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at...